


# 2021 TrACSS Country Report on the Implementation of National Action Plan on Antimicrobial Resistance (AMR)



WHO REGION:

**European Region** 

WORLD BANK INCOME CLASSIFICATION:

**Upper middle income** 

POPULATION:

3 714 000

Antimicrobial resistance (AMR) occurs when pathogens become resistant to the drugs that were used against them, making infections harder and more expensive to treat, increasing healthcare costs and undermining decades of progress in countless health programmes and modern medical procedures.

In a call to action against AMR, Member States adopted the Global Action Plan on AMR (GAP-AMR) in 2015, pledging to develop and implement AMR national action plans (NAP) based on the five objectives of the GAP. The Tripartite AMR Country Self-Assessment Survey (TrACSS) monitors the implementation of these AMR national action plans and is administered annually. It is currently in its fifth iteration, which saw the

highest response rate so far with 163 of 194 (84%) of Member States participating in the survey. However, more than 90% of those countries noted that COVID-19 had had a negative impact on development and implementation of national plans to tackle AMR. Globally, the data from TrACSS indicates an urgent need to strengthen political commitment, to make more resources available, and to build awareness about AMR.

This report focuses on the country's individual TrACSS responses to human health indicators and provides a 5-year overview of country TrACSS responses, and benchmarks country responses against regional and global levels on eight key AMR indicators.

Sectors involved in NAP development and implementation

#### **Summary of AMR Governance in 2021**

### 

#### Resources

AMR resource pack; https://www.who.int/activities/supporting-countries-with-national-action-plan-implementation

WHO implementation handbook for NAPs on AMR: https://www.who.int/publications/i/item/9789240041981

TrACSS Database: https://amrcountryprogress.org



# Overview of country responses to 2017 - 2021 TrACSS Questionnaire

no capacity

limited capacity

developed capacity

demonstrated capacity

sustained capacity

2017 2018 2019 2020 2020

AMI	R Gov	ernance and Coordination	2017	2018	2019	2020	2021
	4.1	Multisector and One Health coordination	B_		<u>C</u> _	<b>D</b>	<b>D</b>
	5.1	Country progress with development of a national action plan on AMR	D	Ε	E	D	D
GAP Objective 1 - Improve awareness and understanding of AMR							
	6.1	Raising awareness and understanding of AMR risks and response	<u>C</u>	E	E	_ <u>C</u> _	D
	6.2	Training and professional education on AMR in the human health sector	D_	_ <mark>C</mark> _	E		<u>C</u> -
	6.3	Training and professional education on AMR in the veterinary sector	<b>A</b>	Ø	<b>A</b>	_ <mark>C</mark> _	_ <mark>C</mark> -
	6.4	Training and professional education on AMR in farming, food, the environment sectors		Ø	A	A	<b>A</b> -
GAP objective 2 - Strengthen knowledge through surveillance and research							
	7.1	National monitoring system for consumption and rational use of antimicrobials in human health	D	D	<u>C</u>	A	A
	7.2	National monitoring system for antimicrobials sale or use for animals (sales/use)*		Ø	A	A	<b>Y</b> -
	7.3	National monitoring system for pesticide use in plant production including antimicrobial pesticides	•	<b>-</b>	A	A	A
	7.4	National surveillance system for AMR in humans	B_		<u>C</u> _	D_	D-
	7.5.a	National surveillance system for AMR in animals		Ø	<b>A</b>		A
	7.5.c	National surveillance system for AMR in food (animal and plant origin)		Ø	<u>C</u> _	<u>C</u> _	A
GAP objective 3 - Reduce the incidence of infection							
	8.1	Infection Prevention and Control (IPC) in human health care		_ <mark>C</mark> _	D	<u>C</u> _	<u>C</u> -
	8.2	Good health, management and hygiene practices to reduce the use of antimicrobials ——and minimize development and transmission of AMR in animal production			В		

8.3 Good management and hygiene practices to reduce the development and

transmission of AMR in food processing

<sup>\*</sup> Response format changed in 2021





# **Overview of country responses to 2017 - 2021 TrACSS Questionnaire**

no capacity

limited capacity

developed capacity

demonstrated capacity

sustained capacity

2017 2018 2019 2020 2021


GAP Objective 4 - Optimize the use of antimicrobials				2018	2019	2020	2021		
	9.1	Optimizing antimicrobial use in human health		_ <mark>C</mark> _	<mark>C</mark> _	_ <u>C</u> _	<u> </u>		
	9.1.1	Adoption of "AWaRe" classification of antibiotics in the National Essential Medicines ———List	<b>•</b>	•	•	B	<u> </u>		
	9.2	Optimizing antimicrobial use in animal health (terrestrial and aquatic)		_ • -			<u> </u>		
	9.3	Optimizing antimicrobial pesticide such as bactericides and fungicides use in plant — production		- • -		Ø	A		
Use of data and regulations to address AMR (Yes/No)									
	5.4.1	Country has laws on prescription and sale of antimicrobials, for human use		_ • -	Y	Y	<u>Y</u> -		
	5.4.2	Country has laws on prescription and sale of antimicrobials for animal use		_ • -	Y	-N-	<u>N</u> -		
	5.4.3	Country has laws that prohibits the use of antibiotics for growth promotion in the absence of risk analysis		- • -	?	?	<b>Y</b>		
	5.4.4	Country has legislation on marketing of pesticides including antimicrobial pesticides, used in plant production	<b>—</b> • –	- • -		-N-	N		
	7.6.a	Country uses relevant AM consumption and/or AMR data to amend national strategy in human health including WASH	<b>— •</b> –	_ • _		Y	<b>Y</b> -		
	7.6.b	Country uses relevant AM consumption and/or AMR data to amend national strategy—in animal health	<b>—</b> • –	- • -		N	<b>Y</b>		





# Global, Regional and National Responses in 2021


TrACSS asks for a rating of national capacity and progress on a five-point scale (A to E), with the levels A-B representing limited capacity, and levels C-E representing nationwide implementation for most indicators. Countries should be aiming to reach levels C-E on all indicators.
















# Global, Regional and National Responses in 2021


TrACSS asks for a rating of national capacity and progress on a five-point scale (A to E), with the levels A-B representing limited capacity, and levels C-E representing nationwide implementation for most indicators. Countries should be aiming to reach levels C-E on all indicators.













### Moving forward: Global messages for action

While a holistic and a people-centred approach is needed to ensure effective implementation of NAPs (human health sector) in countries, targeted efforts are also required in areas where global progress has been uneven over the past five years:

Implementing AMR NAP – majority of countries have developed AMR NAPs, but there is an urgent need expedite the prioritization, costing, funding, implementation, and monitoring of NAPs. AMR NAPs should also be linked to national health sector strategies and health security plans and budgets, and other development plans, including the United National Sustainable Development Cooperation Framework (UNSDCF).

**Establishing functional multisector working groups** – countries need to build capacity to ensure the effective

functioning of AMR multisectoral coordination structures. These structures underpin AMR NAP prioritization, implementation, and monitoring, through periodic review of data, including from TrACSS.

Advancing awareness and education on AMR - systemic and formal inclusion of AMR in health workforce curricula is needed to enhance knowledge among key groups, as are targeted awareness campaigns for key stakeholders, including primary and secondary school students.

Establishing monitoring systems for Antimicrobial consumption – build and strengthen capacity for monitoring of antimicrobial consumption/use in countries. Almost half (45%) of countries report having either no plan or an unimplemented plan for monitoring antimicrobial consumption.

Enhance data quality and use - strengthen lab and diagnostic capacity, including quality assurance and uninterrupted supply of consumables that is essential for the collection of AMR surveillance data. This data can be used to revise treatment guidelines, strengthen IPC measures in healthcare facilities, and strengthen antimicrobial stewardship efforts.

#### Implementing national IPC programmes

- strengthen country capacity for nationwide implementation of infection prevention and control (IPC) programmes developed based on WHO guidelines. Scaling up of water, sanitation, and hygiene (WASH) measures in healthcare facilities and routine immunization efforts are also integral parts of addressing AMR.

#### Moving forward: Regional messages for country action in the European Region

Implementing AMR NAP - Most of the countries (86%) within the WHO European region reported having developed a National Action Plan (NAP). The focus for the coming years should be on costing the implementation of NAPs, allocating the necessary human and financial resources and putting in place an effective system for monitoring and evaluating the implementation of activities.

Establishing functional multisector working groups - Over half of the countries in the WHO European region reported having functional multisectoral coordination. In the countries it remaining remains challenging to convene and engage all relevant sectors in a true One Health approach. Countries are encouraged to consult the available guidance

materials that clarify the roles and responsibilities for multisector working group members and suggest terms of reference to ensure an active and efficient coordination of NAP implementation activities.

Establishing monitoring systems for antimicrobial consumption - Although most countries in the European region monitor Antimicrobial consumption, countries are urged to invest in comprehensive surveillance systems to fully understand the patterns of prescription and antibiotic consumption. This will support the of effective design antimicrobial stewardship systems to prevent and control the spread of resistance.

**Enhance data quality and use** - Countries should strive to have a

consistent, standardized approach for collecting and reporting resistance data and interpreting the results to guide clinical and policy decisions in healthcare facilities. At the national, regional and global level, collecting surveillance data should provide an overview of trends and patterns of resistance, and lead to the development of a common approach for assessing the burden of disease and the economic cost associated with AMR.